{"id":"W3029806582","doi":"10.1200/jco.2020.38.15_suppl.8005","title":"KEYNOTE-204: Randomized, open-label, phase III study of pembrolizumab (pembro) versus brentuximab vedotin (BV) in relapsed or refractory classic Hodgkin lymphoma (R/R cHL).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":true,"ca_institutions":"Jewish General Hospital; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Brentuximab vedotin; Internal medicine; Pembrolizumab; Oncology; Refractory (planetary science); Lymphoma; Hodgkin lymphoma; Cancer; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002034597,0.0020313,0.002183269,0.0004681616,0.0004355587,0.001284271,0.00148222,0.002079231,0.01069124],"category_scores_gemma":[0.001548328,0.0008156726,0.001103993,0.0004221948,0.001101262,0.001426997,0.0005393783,0.003576263,0.002051203],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001068447,"about_ca_system_score_gemma":0.001633628,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007140229,"about_ca_topic_score_gemma":0.002354094,"domain_scores_codex":[0.9994546,0.0002913804,0.00002887975,0.00008905249,0.00003678154,0.00009938835],"domain_scores_gemma":[0.9991876,0.0001865724,0.0001793869,0.00005388341,0.00004268671,0.0003498718],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9641711,0.01472719,0.0004551954,0.0006939481,0.0004455312,0.00005241426,0.00004570359,0.0003202249,0.004856835,0.0001363691,0.00136208,0.01273344],"study_design_scores_gemma":[0.9291776,0.0687793,0.0006321458,0.0000222906,0.0001539701,0.00003333221,0.00001506737,0.0001909693,0.0002938054,0.00009414482,0.0005992356,0.000008205237],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9727526,0.004044542,0.001060682,0.001076775,0.0008024588,0.01231747,0.003882361,0.0002974781,0.003765617],"genre_scores_gemma":[0.9735878,0.002629306,0.002102124,0.002074256,0.0005433635,0.01091497,0.002897461,0.0000518197,0.00519884],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01069124,"threshold_uncertainty_score":0.03576571,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2539880172298434,"score_gpt":0.5011283891179645,"score_spread":0.2471403718881212,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}